The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.
May 13th 2024
In case you missed any, below is a recap of every episode of OncLive On Air that aired in April 2024.
Learning to Tailor Targeted and Immune Therapy in Lung Cancer
December 14th 2020Faculty of the MedStar Georgetown University Hospital-hosted Institutional Perspectives in Cancer webinar on lung cancer spotlight key advances made with targeted therapies in lung cancer, the ways in which immunotherapy has complicated treatment decisions, and more!
Fruquintinib Enters Phase 3 Trial for Metastatic Colorectal Cancer
December 7th 2020December 7, 2020 - The survival benefit of the novel agent fruquintinib will be tested during the phase 3 FRESCO-2 trial in patients with metastatic colorectal cancer who are either intolerant to or have received 3 prior lines of chemotherapy.
Huntsman Homes in on the Integration of Precision Medicine in Oncology
December 3rd 2020In our exclusive interview, Dr. Huntsman discusses the elements of precision medicine that have contributed to its growth in the field of oncology, some of the setbacks regarding its integration, and areas of research that have the potential to propel precision medicine to the next tier of scientific discovery and application.
FDA Approves Naxitamab-gqgk for Relapsed/Refractory High-Risk Neuroblastoma
The FDA has approved naxitamab-gqgk (Danyelza) for use in combination with granulocyte-macrophage colony-stimulating factor as a treatment for pediatric patients 1 year of age and older and adult patients with relapsed/refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior treatment.
TILs, the Ultimate in Personalized Immunotherapy, Move Closer to Market
November 24th 2020November 24, 2020 - Until now, the field of cell-based immunotherapy has been dominated by chimeric antigen receptor (CAR) T cells, with groundbreaking FDA approvals for 3 drugs across several types of hematologic malignancies. In solid tumors, however, CAR T-cell therapies have yet to gain ground.
Oxnard on Opening the Door for Precision Medicine in Lung Cancer
November 23rd 2020In our exclusive interview, Dr. Oxnard explained how precision medicine has affected the treatment landscape of lung cancer, discussed the current capabilities of liquid biopsy, and forecasted the future of precision oncology in the field.
Lorlatinib Data Published in NEJM Underscore Benefits Over Crizotinib in ALK+ NSCLC
November 19, 2020 - Lorlatinib has been found to significantly prolong progression-free survival, elicit a higher overall and intracranial response, and improve quality of life compared with crizotinib in treatment-naïve patients with advanced ALK-positive non–small cell lung cancer.
Real-World Impact of Low-Grade AEs Needs a Closer Look
November 18th 2020Although PARP inhibitors are generally reasonably well tolerated, certainly compared with platinum and other routinely employed cytotoxic antineoplastic drugs, the majority of patients receiving PARP inhibitors in multiple reported clinical trials reported low-grade nausea and fatigue.
FDA Approves PD-L1 IHC 22C3 pharmDx as Companion Diagnostic for Pembrolizumab in TNBC
November 16, 2020 — The FDA has approved the PD-L1 IHC 22C3 pharmDx to aid in the identification of patients with triple-negative breast cancer who are eligible to receive the PD-1 inhibitor pembrolizumab.
Saba Speaks to Tipifarnib and Targeting HRAS in Head and Neck Cancer
November 12th 2020In our exclusive interview, Nabil F. Saba, MD, FACP, sheds light on the implications of targeting HRAS in head and neck squamous cell carcinoma, details the data that has been reported to date with tipifarnib, and shares his expectations for the ongoing KO-TIP-007 trial.
Initial Data from NCI-MATCH Spotlight the Growing Need for Precision Medicine in Oncology
November 11th 2020Keith T. Flaherty, MD, discusses the rationale to conduct the NCI-MATCH trial, key findings from the recent publication, and potential permutations of the trial design that could further the role of precision medicine in oncology.
Adagrasib Shows Early Efficacy in KRAS G12C-Mutant NSCLC and CRC
November 11th 2020Adagrasib, a novel agent aimed at KRAS G12C mutations, has demonstrated early signs of efficacy in patients with advanced non–small cell lung cancer and colorectal cancer whose tumors harbor the alteration, raising hopes for a new therapy against a challenging oncogenic target.
MET, RET, and TRK Inhibitors Achieve Standard-of-Care Status in Lung Cancer
November 9th 2020Alterations in MET, RET, and NTRK have become established actionable drivers of oncogenesis in lung cancer, and therapeutics targeting these aberrations have since obtained regulatory approval from the FDA and have been incorporated into treatment guidelines.
Aggarwal and Gandara on Incorporating Liquid Biopsies Into the Lung Cancer Armamentarium
November 9th 2020In our exclusive interview, Dr. Aggarwal and Dr. Gandara discuss the evolution of liquid biopsy in lung cancer, explain the clinical implications of recent liquid biopsy approvals, and forecast the future of liquid biopsy in the field.
FDA Approves FoundationOne Liquid CDx as Companion Diagnostic for Olaparib in Prostate Cancer
The FDA has approved the FoundationOne Liquid CDx for use as a companion diagnostic with olaparib, which is indicated for select patients with deleterious or suspected deleterious germline or somatic homologous recombination repair gene–mutated metastatic castration-resistant prostate cancer.